The pathology report concluded the presence of a metastatic, high-grade malignant tumor with a neuroendocrine profile and unknown primary location; the absent CgA immunoreactivity could argue in favor of a NEC because this tumor entity occasionally downregulates CgA expression upon tumoral de-differentiation. The gene discussed is CGA; the disease is cancer.